Biopharmaceutics Group, Global Clinical Management, Dr. Reddy's Laboratories Ltd., Integrated Product Development Organization (IPDO), Bachupally, Medchal Malkajgiri District, Hyderabad, 500 090, Telangana, India.
Eur J Clin Pharmacol. 2024 Dec;80(12):1903-1922. doi: 10.1007/s00228-024-03763-w. Epub 2024 Oct 8.
In silico modeling and simulation techniques such as physiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics modeling (PBBM) have demonstrated various applications in drug discovery and development. Virtual bioequivalence leverages these computation tools to predict bioequivalence between reference and test formulations thereby demonstrating possibilities to reduce human studies. A pre-requisite for virtual bioequivalence is development of validated virtual population that depicts the same variability as that of observed in clinic. This development, validation and optimization of virtual population is a key attribute of virtual bioequivalence based on which conclusion of bioequivalence is made.
Various strategies for optimization of virtual population based on appropriate considerations of physicochemical, physiological and disposition aspects are demonstrated with the help of six diverse case studies of immediate and modified release formulations. Once the virtual population is optimized to match in vivo variability, it can be used for various applications such as biowaivers, dissolution specification justification, f2 mismatch, establishing dissolution safe space, etc. In this review article, we attempted to describe various methodologies and approaches for optimization of virtual population using Gastroplus.
Strategies based on optimization of virtual population with emphasis on specific and sensitive parameters were portrayed. We have further elucidated considerations related to study design, in vivo variability, sample size for optimization of virtual population from Gastroplus perspective.
We believe that this review article provides a step-by-step process for virtual population optimization for interest of biopharmaceutics modeling scientists in order to ensure reliable and credible physiological models.
计算建模和模拟技术,如基于生理学的药代动力学(PBPK)和基于生理学的生物药剂学建模(PBBM),在药物发现和开发中已经展示了各种应用。虚拟生物等效性利用这些计算工具来预测参比制剂和试验制剂之间的生物等效性,从而展示了减少人体研究的可能性。虚拟生物等效性的前提是开发验证的虚拟人群,该人群描绘出与临床观察到的相同的变异性。虚拟人群的开发、验证和优化是基于虚拟生物等效性的关键属性,基于此可以得出生物等效性的结论。
通过六个即时释放和改良释放制剂的案例研究,展示了基于物理化学、生理学和处置方面的适当考虑来优化虚拟人群的各种策略。一旦虚拟人群被优化以匹配体内变异性,它就可以用于各种应用,如生物豁免、溶解规范证明、f2 不匹配、建立溶解安全空间等。在这篇综述文章中,我们试图描述使用 Gastroplus 优化虚拟人群的各种方法和方法。
描绘了基于虚拟人群优化的策略,重点是特定和敏感的参数。我们进一步阐述了从 Gastroplus 角度考虑与研究设计、体内变异性、优化虚拟人群所需样本量相关的注意事项。
我们相信,这篇综述文章为虚拟人群优化提供了一个逐步的过程,以确保生物药剂学建模科学家的可靠和可信的生理模型。